Pair page
BPC-157 Fragment with TB-500 Fragment 17-23
Mechanism-tag overlap and published literature for BPC-157 Fragment and TB-500 Fragment 17-23, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
derivative-of-bpc-157tissue-repair
actin-binding-domainthymosin-4-active-fragment
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying BPC-157 Fragment and TB-500 Fragment 17-23 have published these mechanism-level observations. Not a co-administration recommendation.
The closest mechanistic analog in the "fragment of a tissue-repair peptide" category. Stacked together as a minimalist Wolverine analog. Mechanistically complementary in theory (local NO/VEGFR2 from BPC-157 fragment + actin-driven cell migration from TB-500 fragment) but with even less combination evidence than the parent stack.
Quick facts
BPC-157 Fragment
TB-500 Fragment 17-23
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | BPC-157 Fragment | Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (Parent BPC-157 systematic review — does not address fragment-specific evidence; included as… PMID 40756949 | systematic review |
| — | BPC-157 Fragment | ClinicalTrials.gov. Study of PL 14736 in Subjects With Ulcerative Colitis. NCT05765058. (Parent peptide trial — no fragment-specific trial registered.) | human trial |
| 2025 | BPC-157 Fragment | Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. (Parent peptide human pilot — does not apply to fragment.) PMID 40131143 | human pilot |
| 2024 | BPC-157 Fragment | Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. | human pilot |
| 2020 | BPC-157 Fragment | Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. (Parent BPC-157 toxicology — no LD1 in mice/rats/rabbits/dogs.) | preclinical, in vivo |
| — | BPC-157 Fragment | Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. (Clarifies BPC-157 nomenclature as… | preclinical, in vivo |
| 2025 | BPC-157 Fragment | McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. (Parent peptide; raises evidence-quality concerns applicable to fragment by extension.) PMID 40789979 | review |
| 2024 | BPC-157 Fragment | Sikiric P, Sever M, Krezic I et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract, significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organ protection. Inflammopharmacology.… | review |
| 2026 | BPC-157 Fragment | WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (BPC-157 family banned under S0; fragment plausibly included by analogy.) | regulatory / registry |
| 2025 | BPC-157 Fragment | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (BPC-157 fragment shorter sequences are not specifically listed; parent BPC-157 is Category 2.) | regulatory / registry |
| — | BPC-157 Fragment | USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. (Applies to parent and by extension to fragment.) | regulatory / registry |
| 2025 | BPC-157 Fragment | Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. (Parent peptide; reviews structural features including the GE-PPP-GK mot… PMID 40005999 | research article |
| 2023 | TB-500 Fragment 17-23 | Sosne G, Kim C, Kleinman HK. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2023;24(1):554. (Full-length parent… | human trial, Phase 3 |
| 2017 | TB-500 Fragment 17-23 | Shaw G, Lee-Barthel A, Ross ML, Wang B, Baar K. Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis. Am J Clin Nutr. 2017;105(1):136-143. PMID: 27852613. (Substrate-side adjunct reference.) PMID 27852613 | mechanism / discovery |
| 1981 | TB-500 Fragment 17-23 | Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-1166. PMID: 6940133. (Parent molecule discovery.) PMID 6940133 | mechanism / discovery |
| 2025 | TB-500 Fragment 17-23 | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. Thymosin β4 and derivatives prohibited since 2011. | regulatory / registry |
| 2025 | TB-500 Fragment 17-23 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2015 | TB-500 Fragment 17-23 | Sosne G, Kleinman HK. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110-5117. PMID: 26241398. PMID 26241398 | research article |
| 2012 | TB-500 Fragment 17-23 | Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294. PMID 22074294 | research article |
| 2010 | TB-500 Fragment 17-23 | Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. PMID: 20179146. (Defines which Tβ4 activities map to which short sequences.) PMID 20179146 | research article |
| 2010 | TB-500 Fragment 17-23 | Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PMID: 20536465. PMID 20536465 | research article |
| 2007 | TB-500 Fragment 17-23 | Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969. PMID 17108969 | research article |
| 2004 | TB-500 Fragment 17-23 | Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037010. PMID 15037010 | research article |
| 2004 | TB-500 Fragment 17-23 | Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145. (Cardiac progenitor activity — not reproduced by fragm… PMID 15565145 | research article |
Related pair pages
More research context
Frequently asked
Have BPC-157 Fragment and TB-500 Fragment 17-23 been studied together?
Researchers have published mechanistic-level co-administration discussion of BPC-157 Fragment and TB-500 Fragment 17-23. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do BPC-157 Fragment and TB-500 Fragment 17-23 share?
BPC-157 Fragment and TB-500 Fragment 17-23 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of BPC-157 Fragment and TB-500 Fragment 17-23?
BPC-157 Fragment: Research-only. TB-500 Fragment 17-23: Research-only; no human trials. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on BPC-157 Fragment and TB-500 Fragment 17-23?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the BPC-157 Fragment profile and the TB-500 Fragment 17-23 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026